Fig. 7: Pharmacological approaches to the hypoxia pathway. | Experimental & Molecular Medicine

Fig. 7: Pharmacological approaches to the hypoxia pathway.

From: EGLN1 (PHD2) role in tumor microenvironment: insights for therapeutic targeting

Fig. 7

Several PHD enzymes inhibitors such as roxadustat, daprodustat and vadadustat have been developed for the treatment of anemia. Belzutifan is a small molecule specifically inhibiting the dimerization of HIF-2α with HIF-β. Inhibitors of the HIF transcriptional target VEGF have been used for more than 20 years for cancer treatment. Created in https://BioRender.com.

Back to article page